KINDERÄRZTE.SCHWEIZ 3/2020

33 03 / 2020 FORTB I LDUNG: THEMENHEFTTE I L K I N D E R Ä R Z T E . SCHWEIZ 33. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007 Jan 24(1):CD001936. 34. Canonica GW, Cox L, Pawankar R et al. Sublingual immunothera- py: World Allergy Organization position paper 2013 update. The World Allergy Organization journal 2014;7:6. 35. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117: 1021–35. 36. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety role. Allergy 2012;67:302–11. 37. Passalacqua G, Garelli V, Sclifo F, Canonica GW. Sublingual immu- notherapy for allergic rhinitis and conjunctivitis. Immunotherapy 2013;5:257–64. 38. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Mall- ing HJ, Valovirta E. Standards for practical allergenspecic immuno- therapy. Allergy 2006;61 Suppl 82:1–20. 39. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal al- lergic rhinitis: a systematic review and indirect comparison. J Aller- gy Clin Immunol. 2013 May;131(5):1361–6. 40. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutane- ous immunotherapy and pharmacotherapy in seasonal allergic rhi- nitis: a comparison based on meta-analyses. J Allergy Clin Immu- nol. 2011 Oct;128(4):791–99 e6. 41. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immuno- therapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol. 2011 Feb;127(2):502-08 e1–6. 42. Abramson MJ, Puy RM, Weiner JM. Injection allergen immu- notherapy for asthma. Cochrane Database Syst Rev. 2010 Aug 4(8):CD001186. 43. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006 Jan;117(1):169–75. 44. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with aller- gen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010 Nov;126(5):942–9. 45. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunother- apy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006 Feb;117(2):263–8. 46. Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: im- proved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol. 2005 Jun;5(3):267–73. 47. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhi- noconjunctivitis. J Allergy Clin Immunol 2006;118:434–40. 48. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338–45. 49. Worm M. Efficacy and tolerability of high dose sublingual immuno- therapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris) 2006;38:355–60. 50. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sub- lingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802–9. 51. Worm M, Rak S, Blay F de et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen ex- tract in adults with allergic rhinoconjunctivitis: results of a double- blind, placebo-controlled study. Clin Transl Allergy 2014;4:7. 52. Bergmann KC, Demoly P, Worm M et al. Efficacy and safety of sub- lingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. 53. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167–73.e7. 54. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pol- len sublingual immunotherapy tablets in pediatric allergic rhino- conjunctivitis. J Allergy Clin Immunol 2009;123:160–6.e3. 55. Wahn U, Klimek L, Ploszczuk A et al. High-dose sublingual immu- notherapy with single-dose aqueous grass pollen extract in chil- dren is effective and safe: a doubleblind, placebo-controlled study. J Allergy Clin Immunol 2012;130:886–93.e5. 56. Mosbech H, Deckelmann R, Blay F de et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) re- duces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568–75.e7. 57. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen aller- gen-specific immunotherapy: a randomized, placebo-controlled, double-blind, doubledummy study. Allergy 2004;59:45–53. 58. Drachenberg K, Pfeiffer P, Urban E. Sublinguale Immuntherapie. Ergebnisse einer randomisierten, doppelblinden, plazebokontrol- lierten Multicenterstudie mit einem standardisierten Birken- und Gräser-/Roggenpollenextrakt. Allergologie 2001;24:525–34. 59. Horak F, Stübner P, Berger UE, Marks B, Toth J, Jäger S. Immuno- therapy with sublingual birch pollen extract. A short-term dou- ble-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165–71. 60. Biedermann T et al. The SQ ree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blid, placebo-con- trolled phase II trial. J Allergy Clin Immunol 2019;143:1058–66.) 61. Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax (®) ) in children. Clinicoecon Outcomes Res 2014;6:187–96. 62. Brüggenjürgen B, Reinhold T, Brehler R et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with aller- gic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316–24. 63. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost ef- fectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906–17. 64. Schädlich PK and Brecht JG. Economic evaluation of specifc im- munotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17: 37–52.